Vaxxas is pioneering a novel vaccination technology known as the High Density Microarray Patch (HD-MAP), which significantly enhances the efficacy of both existing and next-generation vaccines. This innovative approach utilizes a patch embedded with thousands of microprojections that deliver vaccine directly to the skin, targeting the abundant immune cells located just beneath the surface. The HD-MAP technology not only improves the immune response but also offers advantages such as thermostability, which simplifies the logistics of vaccine distribution by eliminating the need for refrigeration. This makes it particularly beneficial for global health initiatives, especially in low- and middle-income countries where access to traditional vaccination methods can be challenging.

The HD-MAP platform is designed for scalability and has been validated through human clinical studies, demonstrating its potential for various applications, including pandemic response and oncology. Vaxxas is actively pursuing collaborations with major pharmaceutical companies to license its technology, thereby enhancing the commercial viability of existing vaccines. Additionally, the company is in the process of in-licensing vaccine candidates to develop new products, such as a next-generation COVID-19 vaccine patch. The HD-MAP's ability to facilitate self-administration and its robust immune response capabilities position Vaxxas as a key player in the future of vaccination technology.

United States

Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.

Vaxxas

Company Details